Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

379 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement.
Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brodie AM, Colditz GA, Johnston SR, Kristensen VN, Lønning PE, McDonnell DP, Osborne CK, Russo J, Santen RJ, Yee D, Hart CS. Come SE, et al. Among authors: lonning pe. Clin Cancer Res. 2005 Jan 15;11(2 Pt 2):861s-4s. Clin Cancer Res. 2005. PMID: 15701878 No abstract available.
A mitochondrial target sequence polymorphism in manganese superoxide dismutase predicts inferior survival in breast cancer patients treated with cyclophosphamide.
Glynn SA, Boersma BJ, Howe TM, Edvardsen H, Geisler SB, Goodman JE, Ridnour LA, Lønning PE, Børresen-Dale AL, Naume B, Kristensen VN, Chanock SJ, Wink DA, Ambs S. Glynn SA, et al. Among authors: lonning pe. Clin Cancer Res. 2009 Jun 15;15(12):4165-73. doi: 10.1158/1078-0432.CCR-09-0119. Epub 2009 Jun 9. Clin Cancer Res. 2009. PMID: 19509150 Free PMC article.
Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer.
Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P; Droloxifene 301 Study Group. Buzdar A, et al. Breast Cancer Res Treat. 2002 May;73(2):161-75. doi: 10.1023/a:1015229630260. Breast Cancer Res Treat. 2002. PMID: 12088118 Clinical Trial.
Intratumoral estrogen disposition in breast cancer.
Haynes BP, Straume AH, Geisler J, A'Hern R, Helle H, Smith IE, Lønning PE, Dowsett M. Haynes BP, et al. Among authors: lonning pe. Clin Cancer Res. 2010 Mar 15;16(6):1790-801. doi: 10.1158/1078-0432.CCR-09-2481. Epub 2010 Mar 9. Clin Cancer Res. 2010. PMID: 20215536
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. Di Leo A, et al. Among authors: lonning pe. Lancet Oncol. 2018 Jan;19(1):87-100. doi: 10.1016/S1470-2045(17)30688-5. Epub 2017 Dec 7. Lancet Oncol. 2018. PMID: 29223745 Clinical Trial.
379 results